Matthew Shawn Morris Sells 63,212 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 63,212 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $25.33, for a total transaction of $1,601,159.96. Following the completion of the sale, the director owned 76,651 shares of the company’s stock, valued at approximately $1,941,569.83. This represents a 45.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Matthew Shawn Morris also recently made the following trade(s):

• On Friday, June 26th, Matthew Shawn Morris sold 88,110 shares of Privia Health Group stock. The stock was sold at an average price of $25.33, for a total transaction of $2,231,826.30.
• On Friday, May 1st, Matthew Shawn Morris sold 17,096 shares of Privia Health Group stock. The shares were sold at an average price of $24.99, for a total transaction of $427,229.04.
• On Monday, May 4th, Matthew Shawn Morris sold 1,017 shares of Privia Health Group stock. The shares were sold at an average price of $24.96, for a total transaction of $25,384.32.

Privia Health Group Stock Up 4.5%

Shares of NASDAQ:PRVA opened at $26.88 on Thursday. The firm has a 50 day moving average of $23.31 and a 200 day moving average of $22.98. The company has a market capitalization of $3.39 billion, a price-to-earnings ratio of 168.01, a price-to-earnings-growth ratio of 2.04 and a beta of 0.83. Privia Health Group, Inc. has a 52 week low of $18.77 and a 52 week high of $27.11.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.11. The business had revenue of $603.85 million for the quarter, compared to the consensus estimate of $560.99 million. Privia Health Group had a return on equity of 2.81% and a net margin of 0.97%.The business’s revenue was up 25.8% compared to the same quarter last year. During the same period last year, the business posted $0.22 EPS. On average, sell-side analysts expect that Privia Health Group, Inc. will post 0.27 EPS for the current year.

Hedge Funds Weigh In On Privia Health Group

Several hedge funds have recently modified their holdings of PRVA. Bayban acquired a new stake in Privia Health Group in the 4th quarter worth approximately $26,000. Hantz Financial Services Inc. increased its stake in Privia Health Group by 456.2% during the 4th quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock valued at $27,000 after purchasing an additional 926 shares in the last quarter. Global Retirement Partners LLC increased its stake in Privia Health Group by 579.8% during the 4th quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock valued at $38,000 after purchasing an additional 1,351 shares in the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of Privia Health Group by 48.0% in the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock worth $85,000 after buying an additional 1,200 shares during the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in shares of Privia Health Group in the fourth quarter worth $93,000. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Evercore set a $26.00 target price on Privia Health Group in a research note on Wednesday, April 8th. Canaccord Genuity Group decreased their price target on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Barclays cut their price objective on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. Finally, Weiss Ratings lowered shares of Privia Health Group from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.15.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.